PRIA Logo™
FloridaSB 10922026Senate

Podiatric Medicine

Sponsored By: Ralph E. Massullo (Republican)

Signed by Governor

AppropriationHealth PolicyAppropriations Committee on Health and Human ServicesRulesHouse Calendar

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

4 provisions identified: 1 benefits, 2 costs, 1 mixed.

Patients get tissue treatment warnings

Advertisements for covered podiatric cell or tissue procedures must clearly say the products are not FDA-approved. They must encourage patients to consult their primary care provider. The notice must be legible, with type at least as large as the largest type elsewhere in the ad. Before treatment, the podiatrist must obtain signed consent from the patient or, when legally needed, the patient's representative. The form must explain the treatment, FDA status, expected results and benefits, serious risks and complications, and alternatives, including no treatment. It must also recommend consulting a primary care provider and use understandable language in an accessible, readable form.

Podiatrists face license renewal training rules

The Florida Board of Podiatric Medicine can require continuing education for license renewal, capped at 40 hours every two years. When the Board sets this requirement, at least 2 hours must cover safe and effective prescribing of controlled drugs. That minimum applies to podiatrists registered with the Drug Enforcement Administration and authorized to prescribe controlled substances. Courses must meet Board-approved standards, and the Board sets specific requirements by rule.

Podiatrists face penalties for prohibited tissue uses

A podiatrist commits a third-degree felony by willfully performing or actively participating in specified treatment or research. The ban covers human cells or tissues derived from a fetus or embryo after an abortion. Selling, making, or distributing computer products created using human cells, tissues, or cell- or tissue-based products also carries that penalty. Podiatrists engaging in this conduct also face professional discipline.

Podiatrists gain treatment options with safeguards

Florida podiatrists can use certain human cell or tissue products not approved by the U.S. Food and Drug Administration (FDA). Uses must stay within their practice scope and involve connective tissue, ligament or tendon repair, wound care, or pain management. Products must be retrieved, made, and stored in an FDA-registered facility. The facility must be certified or accredited by the National Marrow Donor Program, World Marrow Donor Association, Association for the Advancement of Blood and Biotherapies, or American Association of Tissue Banks. Products must contain live cells after thawing; doctors must receive the product lot's test report before use. The section excludes FDA-authorized investigational uses and work performed through employment or contracts for specified accredited institutions. Those institutions must be certified or accredited by the Foundation for the Accreditation of Cellular Therapy, Blood and Marrow Transplant Clinical Trials Network, or Association for the Advancement of Blood and Biotherapies. The product definition excludes organs for transplant, blood, animal tissues, diagnostic products, and patients' own harvested and reimplanted tissue, among other exclusions. The Board of Podiatric Medicine can adopt rules and discipline physicians for violations. The law took effect immediately upon becoming law.

Sponsors & Cosponsors

Sponsor

  • Ralph E. Massullo

    Republican • Senate

Cosponsors

  • Appropriations Committee on Health and Human Services

    Affiliation unavailable

  • Health Policy

    Affiliation unavailable

Roll Call Votes

All Roll Calls

Yes: 190 • No: 0

House vote • 3/10/2026

House Floor Vote

Yes: 112 • No: 0

Senate vote • 2/26/2026

Senate Floor Vote

Yes: 35 • No: 0

Senate vote • 2/24/2026

Rules Vote

Yes: 23 • No: 0

Senate vote • 2/18/2026

Appropriations Committee on Health and Human Services Vote

Yes: 9 • No: 0

Senate vote • 2/11/2026

Health Policy Vote

Yes: 11 • No: 0

Actions Timeline

  1. Chapter No. 2026-124

    6/12/2026

  2. Approved by Governor

    6/11/2026

  3. Signed by Officers and presented to Governor

    6/9/2026

  4. Ordered enrolled

    3/17/2026Senate

  5. CS passed; YEAS 112, NAYS 0

    3/10/2026House

  6. Read 3rd time

    3/10/2026House

  7. Added to Third Reading Calendar

    3/10/2026House

  8. Read 2nd time

    3/10/2026House

  9. 1st Reading (Committee Substitute 2)

    3/9/2026House

  10. Bill added to Special Order Calendar (3/10/2026)

    3/9/2026House

  11. Bill referred to House Calendar

    3/9/2026House

  12. In Messages

    2/26/2026House

  13. Immediately certified -SJ 463

    2/26/2026Senate

  14. CS passed; YEAS 35 NAYS 0 -SJ 447

    2/26/2026Senate

  15. Read 3rd time -SJ 447

    2/26/2026Senate

  16. Read 2nd time -SJ 447

    2/26/2026Senate

  17. Placed on Special Order Calendar, 02/26/26

    2/25/2026Senate

  18. Placed on Calendar, on 2nd reading

    2/25/2026Senate

  19. Favorable by- Rules; YEAS 23 NAYS 0

    2/24/2026Senate

  20. CS/CS by Appropriations Committee on Health and Human Services read 1st time

    2/19/2026Senate

  21. On Committee agenda-- Rules, 02/24/26, 12:00 pm, 412 Knott Building

    2/19/2026Senate

  22. Now in Rules

    2/19/2026Senate

  23. Pending reference review under Rule 4.7(2) - (Committee Substitute)

    2/19/2026Senate

  24. CS by Health Policy read 1st time

    2/18/2026Senate

  25. CS/CS by Appropriations Committee on Health and Human Services; YEAS 9 NAYS 0

    2/18/2026Senate

Bill Text

Related Bills

Back to State Legislation